Altimmune Inc
NASDAQ:ALT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Altimmune Inc
Tax Provision
Altimmune Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Altimmune Inc
NASDAQ:ALT
|
Tax Provision
$681k
|
CAGR 3-Years
50%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Tax Provision
-$2.4B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Tax Provision
-$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Tax Provision
-$1.3B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Tax Provision
-$690m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-37%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Tax Provision
-$681.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-1%
|
|
Altimmune Inc
Glance View
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 47 full-time employees. The company went IPO on 2005-10-06. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The company is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The firm has initiated a Phase II clinical trial of HepTcell and are in Phase II and Phase I clinical development with pemvidutide for multiple indications. The company is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany and Spain, and conducting Its pemvidutide Phase I clinical trial in Australia. Its wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
See Also
What is Altimmune Inc's Tax Provision?
Tax Provision
681k
USD
Based on the financial report for Dec 31, 2025, Altimmune Inc's Tax Provision amounts to 681k USD.
What is Altimmune Inc's Tax Provision growth rate?
Tax Provision CAGR 5Y
-34%
The average annual Tax Provision growth rates for Altimmune Inc have been 50% over the past three years , -34% over the past five years .
